A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban
administered intravenously, either alone or in combination; and the pharmacokinetics and
pharmacodynamics and potential interaction of both agents in a population of healthy
subjects.